COVID vaccines save lives
COVID vaccines reduce deaths from COVID. Large population studies do not support claims of mass vaccine deaths. Rare fatal reactions can occur, and some reported deaths remain unresolved. A death reported after vaccination is a reason to investigate, not proof that vaccination caused it.
On this page
Population studies do not show mass deaths
The French cohort compared 22.7 million vaccinated with 5.9 million unvaccinated adults aged 18–59, followed for a median 45 months. Overall mortality was not increased. Lower mortality is observational and may partly reflect group differences; it is not proof of protection from every cause of death or an answer about every child. Separate effectiveness research supports protection against COVID death.
Rare fatal injuries are real
Adjudicated Korean surveillance identified fatal vaccine-related myocarditis. Particular adenovirus-vector products also caused rare serious clotting reactions. Historical findings must keep their product and time period; they do not establish a current-season death rate for every vaccine.
What the FDA pediatric review found
A review released in 2026 examined 96 reports concerning vaccinations in 2021–2024: two deaths were probably related, five possibly related, 62 unlikely and 27 unassessable. None was classified certain; that does not prove zero vaccine-caused deaths. “Possible” allows an equally likely alternative cause. Data were locked on 14 August 2025; the seven possible/probable cases followed original or bivalent Pfizer formulations. These are reviewed reports, not a population death rate.
Reports start investigations
VAERS reports can reveal a safety signal, but cannot by themselves count vaccine-caused deaths. Investigators examine medical records, timing, background deaths and comparison groups. Underreporting and stimulated reporting both matter; multiplying reports by an arbitrary factor does not establish causation. Myocarditis shows how a signal can lead to a confirmed risk.
Excess deaths need a cause, not just a timeline
Deaths above an expected baseline deserve investigation. A rise after rollout does not isolate vaccination from infection and other changes. Population comparisons and individual case reviews answer different questions; neither justifies an invented worldwide count.
COVID vaccines reduce deaths from COVID.
Keep in mind
- The findings apply to the vaccines, populations and outcomes studied. Personal recommendations depend on your health and current local guidance.
Sources you can check
Publication links open in a new tab, so you can keep your place here.
COVID-19 mRNA Vaccination and 4-Year All-Cause Mortality Among Adults Aged 18 to 59 Years in France (opens in a new tab)
JAMA Network Open, 2025
Large observational comparison, median 45 months. Selection and health differences can affect all-cause mortality; does not settle pediatric risk.
Return to reading ↑Association of 2024–2025 Covid-19 Vaccine with Covid-19 Outcomes in U.S. Veterans (opens in a new tab)
New England Journal of Medicine, 2025
Observational US veteran study with a flu-vaccinated comparator; mostly older men, not every age group.
Return to reading ↑COVID-19 vaccination-related myocarditis: a Korean nationwide study (opens in a new tab)
European Heart Journal, 2023
Adjudicated surveillance includes fatal myocarditis. Historical case ascertainment limits transfer to current doses and other countries.
Return to reading ↑Evidence Review of the Adverse Effects of COVID-19 Vaccination (opens in a new tab)
National Academies, 2024
Conclusions are specific to vaccine product and clinical outcome.
Return to reading ↑FDA memorandum reviewing pediatric deaths reported after COVID-19 vaccination (opens in a new tab)
FDA memorandum, December 2025; released May 2026
Original memorandum at PDF pages 8–15, separate from the cover letter. Reports concern 2021–2024 vaccinations; classifications are not incidence rates.
Return to reading ↑COVID-19 Vaccine Safety Surveillance (opens in a new tab)
FDA
Explains how reports and comparative monitoring identify safety signals.
Return to reading ↑FDA Approves Required Updated Warning in Labeling of mRNA COVID-19 Vaccines Regarding Myocarditis and Pericarditis (opens in a new tab)
FDA, June 2025
Observed 2023–24-formulation incidence in days 1–7 is not an excess-risk estimate. Persistent MRI findings have uncertain long-term meaning.
Return to reading ↑
Detailed research notes and source data
Our longer notes explain how we checked the studies, including disagreements and documents we could not get.
Download the detailed research notes →More research notes: vaccine risks →
More research notes: supporting evidence →
Something unclear or missing?
You can save a feedback note to share with the site owner. The form saves a file on your device; it does not send it to us.
Save a feedback note →About this draft
These pages have not completed expert review. For personal vaccine advice, talk to a clinician who knows your circumstances.
Research checked: . Wording reviewed: 2026-10-15. Version: vaccine-2026-10-15.
We revisit the page when new evidence or corrections change the answer. A public history of corrections is not available yet.